Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ACTILYSE 2 mg is substantial. |
Clinical Added Value
| minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE. |
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
EAwc0F5tBtqaCNQq
Listen
